ATE260649T1 - Pharmazeutische formulierung und dosierform bestehend aus polysacchariden zur kontrollierten wirkstoff-freisetzung im dickdarm - Google Patents

Pharmazeutische formulierung und dosierform bestehend aus polysacchariden zur kontrollierten wirkstoff-freisetzung im dickdarm

Info

Publication number
ATE260649T1
ATE260649T1 AT99305600T AT99305600T ATE260649T1 AT E260649 T1 ATE260649 T1 AT E260649T1 AT 99305600 T AT99305600 T AT 99305600T AT 99305600 T AT99305600 T AT 99305600T AT E260649 T1 ATE260649 T1 AT E260649T1
Authority
AT
Austria
Prior art keywords
dosage form
polysaccharides
colon
active ingredients
controlled release
Prior art date
Application number
AT99305600T
Other languages
English (en)
Inventor
Seung Seo Lee
Chang Baeg Lim
Chaul Min Pai
Sujung Lee
In Park
Gun Seomoon
Heenam Park
Original Assignee
Samyang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Corp filed Critical Samyang Corp
Application granted granted Critical
Publication of ATE260649T1 publication Critical patent/ATE260649T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/06—Pectin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99305600T 1998-07-23 1999-07-15 Pharmazeutische formulierung und dosierform bestehend aus polysacchariden zur kontrollierten wirkstoff-freisetzung im dickdarm ATE260649T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19980029740 1998-07-23
KR1019990014665A KR20000011247A (ko) 1998-07-23 1999-04-23 다당류를이용한대장선택성약물전달조성물및약학제제

Publications (1)

Publication Number Publication Date
ATE260649T1 true ATE260649T1 (de) 2004-03-15

Family

ID=26633955

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99305600T ATE260649T1 (de) 1998-07-23 1999-07-15 Pharmazeutische formulierung und dosierform bestehend aus polysacchariden zur kontrollierten wirkstoff-freisetzung im dickdarm

Country Status (13)

Country Link
US (1) US6413494B1 (de)
EP (1) EP0974344B1 (de)
JP (1) JP4088420B2 (de)
KR (2) KR20000011247A (de)
CN (1) CN1166406C (de)
AT (1) ATE260649T1 (de)
AU (1) AU744183B2 (de)
BR (1) BR9912075B1 (de)
CA (1) CA2336815C (de)
DE (1) DE69915184T2 (de)
ES (1) ES2214813T3 (de)
MX (1) MXPA01000768A (de)
WO (1) WO2000004924A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
DE60025201T2 (de) * 1999-06-09 2006-06-29 Mochida Pharmaceutical Co. Ltd. System für wirkstofffreisetzung im unteren verdauungstrakt
AU1195001A (en) * 1999-10-11 2001-04-23 Monsanto Company Tablets coated with locust bean gum, guar gum or carrageenan gum
EP1313697B1 (de) 2000-08-29 2005-11-30 Nobex Corporation Immunoregulierende verbindungen, deren derivate und ihre verwendung
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
KR100429495B1 (ko) * 2001-02-28 2004-05-03 정명준 단백질 및 다당류를 이용한 이중코팅 유산균 원말의제조방법
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US6645946B1 (en) * 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
EP1383516B1 (de) * 2001-03-27 2011-11-09 Pro-Pharmaceuticals, Inc. Gleichzeitige verabreichung eines polysaccharids mit einem chemotherapeutischen mittel zur behandlung von krebs
EP1414458B1 (de) * 2001-07-06 2007-04-11 Endo Pharmaceuticals Inc. Orale gabe von 6-hydroxy-oxymorphon als analgetikum
PL208484B1 (pl) * 2001-07-06 2011-05-31 Penwest Pharmaceuticals Company Sposoby wytwarzania preparatów oksymorfonu o przedłużonym uwalnianiu
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
WO2003026743A2 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
JP5041651B2 (ja) * 2001-09-28 2012-10-03 ティーエヌティーギャンブル・インコーポレーテッド 生物体成分の送達系
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
WO2003057136A2 (en) 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
WO2004012715A1 (en) * 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
CA2522295C (en) * 2003-04-14 2012-02-07 Fmc Corporation Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom
WO2005007110A2 (en) * 2003-07-11 2005-01-27 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005056022A1 (ja) 2003-12-12 2005-06-23 Taiyo Kagaku Co., Ltd. 腸疾患改善用組成物
US7417037B2 (en) * 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
CA2555304C (en) 2004-02-06 2016-06-28 Nicolas Peter Shortis Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
WO2005079314A2 (en) * 2004-02-13 2005-09-01 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
EP1720579A1 (de) * 2004-02-17 2006-11-15 Wheli Inter AG Galaktomannane und/oder glucomannane zur erhöhung von wirkstoff-bioverfügbarkeit
EP1773767B1 (de) 2004-07-07 2016-03-09 Biocon Limited Synthese von azogebundenen, das immunsystem regulierenden verbindungen
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
US20060079514A1 (en) * 2004-10-13 2006-04-13 Victory Pharma Incorporated Methods and compositions including methscopolamine bromide
US20060079513A1 (en) * 2004-10-13 2006-04-13 Preston David M Methods and compositions including methscopolamine nitrate
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2620469C (en) 2005-09-02 2014-04-01 Amgen Inc. Methods of modulating intestinal fluid balance
US8080579B2 (en) * 2005-10-03 2011-12-20 The Regents Of The University Of Michigan Compositions and methods for treatment of inflammatory bowel disease
US7687608B2 (en) * 2005-10-19 2010-03-30 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
EP2139462B1 (de) 2007-03-30 2014-01-22 Amgen Inc. Calcimimetische verbindungen zur verwendung bei der behandlung von darmerkrankungen
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
CN101134785B (zh) * 2007-08-17 2010-08-18 浙江大学 结肠菌群降解材料及其制备方法和用途
US20090197837A1 (en) * 2008-02-05 2009-08-06 Desai Vivek S Alendronate formulations, method of making and method of use thereof
JP5250285B2 (ja) * 2008-03-26 2013-07-31 富士フイルム株式会社 経口物用被覆材、可食性容器およびそれらを用いた経口物
WO2009126742A2 (en) * 2008-04-08 2009-10-15 Appian Labs, Llc Enzyme mediated delivery system
KR101766619B1 (ko) 2008-12-31 2017-08-08 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US8636069B2 (en) * 2009-09-22 2014-01-28 Halliburton Energy Services, Inc. Wellbore servicing fluid compositions and use thereof
US20110123677A1 (en) * 2009-11-25 2011-05-26 Pepsico, Inc. High acid beverage products and methods to extend probiotic stability
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
US20140154312A1 (en) * 2010-09-17 2014-06-05 Monica Gulati Oral targetted drug delivery system
US20120071410A1 (en) 2010-09-21 2012-03-22 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
HK1211469A1 (en) 2012-08-21 2016-05-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
KR20160061911A (ko) * 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
AU2014250956B2 (en) 2013-04-12 2019-04-04 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
US20150073057A1 (en) * 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
SI2946774T1 (sl) * 2014-05-19 2020-07-31 Tillotts Pharma Ag Obložene kapsule s prirejenim sproščanjem
WO2017042835A1 (en) 2015-09-11 2017-03-16 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical dosage forms of budesonide
KR102669987B1 (ko) 2017-01-09 2024-05-31 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물
BR112019013963A2 (pt) 2017-01-09 2020-04-28 Ardelyx Inc inibidores de antiporte mediado por nhe
CN108851084B (zh) * 2018-06-06 2021-06-15 福建省农业科学院农业工程技术研究所 一种荷载槲皮素的结肠定位胶束及其制备方法
KR102665295B1 (ko) 2021-08-03 2024-05-09 인제대학교 산학협력단 다중코팅 캡슐형 약물 전달 복합체 및 이의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2113221C1 (ru) * 1990-05-04 1998-06-20 Ииссум Рисерч Дивелопмент Компани оф дзе Хебрю Юниверсити оф Иеруcалим Фармацевтическая форма для введения лекарственного средства в ободочную кишку, способ введения лекарственного препарата и способ получения матриц для такой формы
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE9015551U1 (de) * 1990-11-14 1992-03-12 Röhm GmbH, 6100 Darmstadt Orale Arzneiform und Überzugsmittel, enthaltend ein im Colon abbaubares Polysaccarid
FR2688422A1 (fr) * 1992-03-11 1993-09-17 Coletica Microcapsules a parois en polysaccharides contenant des fonctions alcools primaires, et compositions en contenant.
DE4209160A1 (de) * 1992-03-20 1993-09-30 Bauer Kurt Heinz Prof Dr Vernetzte Polysaccharide, Verfahren zu ihrer Herstellung und ihre Verwendung
AU1751997A (en) * 1996-01-30 1997-08-22 Advanced Polymer Systems Inc. Targeted delivery of drugs to the lower gastrointestinal tract
GB9603146D0 (en) * 1996-02-15 1996-04-17 Innovative Tech Ltd Hydrogels

Also Published As

Publication number Publication date
CN1166406C (zh) 2004-09-15
AU4062799A (en) 2000-02-14
DE69915184D1 (de) 2004-04-08
US6413494B1 (en) 2002-07-02
WO2000004924A1 (en) 2000-02-03
EP0974344A2 (de) 2000-01-26
KR20010074641A (ko) 2001-08-04
EP0974344A3 (de) 2000-03-01
KR20000011247A (ko) 2000-02-25
AU744183B2 (en) 2002-02-14
CA2336815C (en) 2005-06-07
DE69915184T2 (de) 2004-12-30
JP4088420B2 (ja) 2008-05-21
CA2336815A1 (en) 2000-02-03
KR100425028B1 (ko) 2004-03-27
MXPA01000768A (es) 2002-04-08
BR9912075A2 (pt) 2010-08-31
BR9912075B1 (pt) 2011-08-23
ES2214813T3 (es) 2004-09-16
EP0974344B1 (de) 2004-03-03
JP2002521346A (ja) 2002-07-16
CN1310630A (zh) 2001-08-29

Similar Documents

Publication Publication Date Title
ATE260649T1 (de) Pharmazeutische formulierung und dosierform bestehend aus polysacchariden zur kontrollierten wirkstoff-freisetzung im dickdarm
DE69008346T2 (de) Arzneistoffabgabe-zusammensetzungen.
BR9808933A (pt) Composição sob forma de microcápsulas ou de implantes, processo de preparação de uma substância hidrossolúvel, substância ativa, acetato de triptorelina, acetato de lanreotìdeo, ou acetato de octreotìdeo, e rna de filamento duplo
DE60036807D1 (de) Verfahren zur herstellung eines pharmazeutischen kaugummis
YU49354B (sh) Oralne tečne formulacije alendronata
NZ311208A (en) Composition comprising an active agent dissolved in a glass-forming carrier comprising a glass-forming substance containing a plasticizer, composition is liquid or jelly-like below 50 degrees
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
AU8227291A (en) Therapeutical composition and process for its preparation
CA2253980A1 (en) Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
CA2369715A1 (en) Fast-dispersing dosage forms containing fish gelatin
CA2395331A1 (en) Pharmaceutical compositions providing enhanced drug concentrations
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
NZ501950A (en) Medicinal compositions for application to mucosa
ATE292961T1 (de) Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
DE69623087D1 (de) Brausemittel und dessen Herstellung
DE3679463D1 (de) Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung.
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
ATE291922T1 (de) Makrolidcitrat-haltige formulierungen mit kontrollierter freisetzung
ZA912793B (en) Pharmaceutical formulations
PL311276A1 (en) Veterinary composition containing a proton pump inhibitor
GB9713140D0 (en) Preparation of pharmaceutical compositions
TR199901250T2 (xx) Tedavi ama�l� ajanlar.
DE69836207D1 (de) Orale pharmazeutische zusammensetzungen mit reduzierter bitterkeit durch geschmacksmaskiermittel
ATE217532T1 (de) Eine didemnin verbindung enthaltende pharmazeutische formulierung
CA2325983A1 (en) Drug delivery of proteins from polymeric blends

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0974344

Country of ref document: EP